sciclone pharmaceuticals Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : sciclone pharmaceuticals

SCLN 11.15

0.0%

Oct 20 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: JEB who wrote (878)	8/20/2001 9:26:08 PM
From: Oak Tree	Read Replies (4) of 1137

Jeb, be careful how much company literature you read. You might find out that neither drug works all that well. The response rates for C225 aren't 80% -- the frequency of head and neck cancers with EGFR is 80% (for colon cancer its about 50%). The company doesn't tell you the response rates just the frequency of tumor positivity. At the ASCO presentation the response rate was about 20%. There were no complete responses!! Also don't get confused about the skin response rate. About 80% of people get a skin rash from C225. The physicians using C225 say that patients who don't get a skin rash don't respond. That doesn't mean that all patients who get a rash do respond. To say it differently, almost all tumors are positive for GLUT1, a protein that allows them to eat glucose even if there is no oxygen around. That doesn't mean that attaching GLUT1 will kill cancer cells. All cancer cells have mitochondria, and mitochondria are required for cells to live. That doesn't mean that a drug that kills mitochondria will work for cancer. Best luck but don't sink too much money into either of these is my recommendation.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next